Anastrozole Use in Postmenopausal Women

Introduction to Anastrozole

• The American Society of Clinical Oncology recommends that anastrozole can be used in postmenopausal women to prevent estradiol conversion by inhibiting the aromatase enzyme, but it is contraindicated in premenopausal women 1, 2, 3

Mechanism and Efficacy

• Anastrozole is a selective non-steroidal aromatase inhibitor that blocks the conversion of adrenal androgens to estrone and estradiol in peripheral tissues, although the exact mechanism is not fully described here 1, 2, 3

Critical Menopausal Status Requirement

• The National Comprehensive Cancer Network recommends that premenopausal women should never receive anastrozole outside of clinical trials because aromatization of adrenal androgens is not a significant source of estradiol in this population 4, 5
• The National Comprehensive Cancer Network also recommends that serial assessment of luteinizing hormone, follicle-stimulating hormone, and estradiol is mandatory to confirm true postmenopausal status before initiating anastrozole 4, 5

Approved Clinical Uses in Postmenopausal Women

• The American Society of Clinical Oncology recommends that anastrozole 1 mg daily for 5 years should be discussed as an option to reduce invasive breast cancer risk in postmenopausal women at increased risk 1, 2, 3
• The American Society of Clinical Oncology also recommends that postmenopausal women with hormone receptor-positive early breast cancer should receive an aromatase inhibitor as initial adjuvant therapy, sequential with tamoxifen, or as extended therapy 4, 5

Mandatory Pre-Treatment Evaluation

• The American Society of Clinical Oncology recommends that before initiating anastrozole, clinicians must evaluate baseline fracture risk and measure bone mineral density 1, 2, 3, 6
• The American Society of Clinical Oncology also recommends that women with severe osteoporosis should not receive anastrozole 2, 3, 6

Essential Bone Protection Strategy

• The American Society of Clinical Oncology recommends that all patients receiving anastrozole require comprehensive bone protection, including calcium and vitamin D supplementation 1, 2, 3, 6, 7
• The American Society of Clinical Oncology also recommends that regular weight-bearing exercise should be encouraged 1, 2, 3, 6
• Anastrozole significantly increases fracture risk compared to tamoxifen (7.1% vs 4.1% after 37 months) 7

Common Side Effects to Counsel Patients About

• The American Society of Clinical Oncology recommends that patients must be informed of the following adverse effects: joint stiffness and arthralgias, vasomotor symptoms, hypertension, and dry eyes and vaginal dryness 1, 2, 3, 6

Stopping Anastrozole Treatment

Introduction to Stopping Anastrozole

• The American Society of Clinical Oncology recommends stopping anastrozole directly without tapering after completing the recommended treatment duration (5 years for risk reduction or adjuvant treatment) in postmenopausal women at high risk of breast cancer, taking into account bone health and side effects 8, 9, 10

Standard Treatment Duration Before Stopping

• For breast cancer risk reduction, anastrozole is prescribed at 1 mg per day for 5 years in postmenopausal women at high risk, with a significant reduction in breast cancer incidence 8, 9, 10

Essential Pre-Stop Evaluation

• The American Society of Clinical Oncology guidelines recommend evaluating bone health before stopping anastrozole, as it significantly increases the risk of fractures, and considering treatment to protect bone health after stopping 9, 10

Post-Stop Surveillance

• The American Society of Clinical Oncology recommends continuing calcium and vitamin D supplementation after stopping anastrozole if bone density is compromised, and encouraging weight-bearing exercise to maintain bone health 9, 10
• Regular mammographic surveillance should be maintained according to standard protocols, as the benefit of reduced breast cancer risk persists after stopping 5 years of treatment 8, 10

Pitfalls to Avoid

• The American Society of Clinical Oncology guidelines advise against stopping anastrozole prematurely without a valid medical reason, as this compromises treatment efficacy, and emphasize the importance of evaluating bone health before and after stopping 8, 9

Anastrozole Side Effects and Risks in Postmenopausal Women with Breast Cancer

Musculoskeletal and Bone Health Effects

• The National Comprehensive Cancer Network recommends that anastrozole is associated with a higher risk of fractures (10% vs 7%) and musculoskeletal events compared to tamoxifen 11
• Arthritis and arthrosis occur more frequently with anastrozole compared to tamoxifen, according to the Journal of the National Comprehensive Cancer Network 11
• Deep vein thrombosis rates are lower with anastrozole than tamoxifen, as reported by the Journal of the National Comprehensive Cancer Network 11

Cardiovascular Risks

• The National Comprehensive Cancer Network guidelines suggest that anastrozole is associated with a lower risk of thromboembolic events, but a higher risk of cardiovascular events in women with pre-existing heart disease 11

Monitoring and Follow-up

• The National Comprehensive Cancer Network recommends interval history and physical examination every 6-12 months for 5 years, then annually, as well as annual diagnostic mammography 11

Anastrozole as Adjuvant Endocrine Therapy for Post‑menopausal Women with HR⁺/HER2⁺ Stage II Breast Cancer

Guideline Recommendations (American Society of Clinical Oncology)

Efficacy Evidence (ATAC Trial)

HER2‑Positive Considerations

Treatment Duration and Extended Therapy

Bone Health and Fracture Risk

Adverse‑Effect Profile Compared with Tamoxifen